Morgan Stanley Upgrades Amicus Therapeutics to Overweight, Raises Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Jeffrey Hung has upgraded Amicus Therapeutics (NASDAQ:FOLD) from Equal-Weight to Overweight and increased the price target from $15 to $20.

December 19, 2023 | 2:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Amicus Therapeutics was upgraded by Morgan Stanley from Equal-Weight to Overweight with a raised price target from $15 to $20.
Upgrades by major analysts like Morgan Stanley can lead to increased investor confidence and a potential rise in stock price. The upgrade from Equal-Weight to Overweight suggests a bullish outlook on the stock, while the increase in price target from $15 to $20 represents a significant expected upside, which could attract more buyers in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100